Taming the dragon: genomic biomarkers to individualize the treatment of cancer

Do predictive signatures really predict response to cancer chemotherapy? 

(2011) Piet Borst et al.   CELL CYCLE

Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology

(2010) Keith A. Baggerly et al.   Annals of Applied Statistics

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome

(2010) Michael Hölzel et al.   CELL

Circulating tumor cells: a window into cancer biology and metastasis

(2010) Shyamala Maheswaran et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors

(2010) David J. McBride et al.   GENES CHROMOSOMES & CANCER

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

(2010) Wendy De Roock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

(2010) Stefan Gross et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

(2010) William Lee et al.   NATURE

Genome remodelling in a basal-like breast cancer metastasis and xenograft

(2010) Li Ding et al.   NATURE

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

International network of cancer genome projects

(2010) Thomas J. Hudson (Chairperson) et al.   NATURE

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

(2010) Jordi Barretina et al.   NATURE GENETICS

ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas

(2010) Kimberly C. Wiegand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma

(2010) Siân Jones et al.   SCIENCE

Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies

(2010) I. Astsaturov et al.   Science Signaling

Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases

(2010) A. Moritz et al.   Science Signaling

Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing

(2010) R. J. Leary et al.   Science Translational Medicine

Circulating tumour cells in cancer patients: challenges and perspectives

(2010) Klaus Pantel et al.   TRENDS IN MOLECULAR MEDICINE

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

(2009) F. P. S. Santos et al.   BLOOD

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

(2009) Anurag Singh et al.   CANCER CELL

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

(2009) D. Etemadmoghadam et al.   CLINICAL CANCER RESEARCH

Next-Generation Sequencing of Plasma/Serum DNA: An Emerging Research and Molecular Diagnostic Tool

(2009) Y.M. D. Lo et al.   CLINICAL CHEMISTRY

I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

(2009) AD Barker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

(2009) Frédéric Bibeau et al.   JOURNAL OF CLINICAL ONCOLOGY

How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question

(2009) T. Fojo et al.   JNCI-Journal of the National Cancer Institute

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

(2009) Sohrab P. Shah et al.   NATURE

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

A small-cell lung cancer genome with complex signatures of tobacco exposure

(2009) Erin D. Pleasance et al.   NATURE

A comprehensive catalogue of somatic mutations from a human cancer genome

(2009) Erin D. Pleasance et al.   NATURE

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing

(2009) Andreas Gnirke et al.   NATURE BIOTECHNOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

(2009) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH

(2008) Simon A. Joosse et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer

(2008) Elizabeth Iorns et al.   CANCER CELL

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

(2008) U. McDermott et al.   CANCER RESEARCH

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2008) P. J.A. Eichhorn et al.   CANCER RESEARCH

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

(2008) N. T. Ihle et al.   CANCER RESEARCH

Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib

(2008) M. Hazarika et al.   CLINICAL CANCER RESEARCH

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH

Clinical Application of the 70-Gene Profile: The MINDACT Trial

(2008) Fatima Cardoso et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Testing Scandal Shines Spotlight on Black Box of Clinical Laboratory Testing

(2008) K. Hede   JNCI-Journal of the National Cancer Institute

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

(2008) A Hochhaus et al.   LEUKEMIA

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

(2008) Timothy J. Ley et al.   NATURE

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE

Circulating mutant DNA to assess tumor dynamics

(2008) Frank Diehl et al.   NATURE MEDICINE

Reverse-phase protein lysate microarrays for cell signaling analysis

(2008) Brett Spurrier et al.   Nature Protocols

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

(2008) Shyamala Maheswaran et al.   NEW ENGLAND JOURNAL OF MEDICINE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE